Hematology: ESAs to treat anemia--balancing the risks and benefits.
Glaspy
John
J
University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095-6956, USA. jglaspy@mednet.ucla.edu
D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001803:Blood Transfusion; D006397:Hematinics / Q000009:adverse effects*; D006405:Hematology; D006801:Humans; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016019:Survival Analysis
D000970:Antineoplastic Agents; D006397:Hematinics
Lancet. 2009 May 2;373(9674):1532-42
19410717
J Clin Oncol. 2008 Mar 1;26(7):1040-50
18227526
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003407
16856007
J Natl Compr Canc Netw. 2008 Jul;6(6):565-75
18597710
J Natl Cancer Inst. 2005 Apr 6;97(7):489-98
15812074
J Clin Oncol. 2005 Sep 1;23(25):5960-72
16087945
Annu Rev Med. 2009;60:181-92
18980468
J Natl Cancer Inst. 2006 May 17;98(10):708-14
16705125